Cytomegalovirus Cmv clinical trials

Explore recruiting cytomegalovirus cmv clinical trials.

Recruiting cytomegalovirus cmv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cytomegalovirus Cmv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Finland, Italy, Spain, France, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter randomized two arms study evaluating the efficacy of prophylactic Rituximab in EBV negative kidney transplant recipients on incidence of EBV primary infection and post-transplant lymphoproliferative disorders - REPLY

France

Therapeutic use (Phase IV) EU CTIS Study details

Comparison of the efficacy and safety of valaciclovir in the prevention of transmission and treatment of intrauterine infection in pregnant women with primary cytomegalovirus infection depending on the used drug dose - the first Polish non-commercial non-inferiority clinical trial.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

LUCY-1 - Letermovir/valganciclovir combination versus valganciclovir monotherapy for treatment of cytomegalovirus (CMV) infections in kidney transplant recipients

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

"Full title (English): A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT) "

Spain, Belgium, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

Cytomegalovirus Cmv trials by city

Cytomegalovirus Cmv in Toronto Cytomegalovirus Cmv in Vancouver Cytomegalovirus Cmv in Montreal Cytomegalovirus Cmv in Calgary Cytomegalovirus Cmv in Edmonton Cytomegalovirus Cmv in Ottawa Cytomegalovirus Cmv in Winnipeg Cytomegalovirus Cmv in Quebec City Cytomegalovirus Cmv in Hamilton Cytomegalovirus Cmv in Kitchener Cytomegalovirus Cmv in London Cytomegalovirus Cmv in Halifax Cytomegalovirus Cmv in New York Cytomegalovirus Cmv in Los Angeles Cytomegalovirus Cmv in Chicago Cytomegalovirus Cmv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease